Screened 2026-09-11 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Lantheus Holdings, Inc. holds its Markdown at $100.25. Consolidating, no directional conviction, held for 183 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 183 days
Price at the screen
$100.25
Valuation
23.98 trailing · 15.72 forward price to earnings
Values screen
PASS· score 70.0
Beta
-0.03
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
27.81%
Below 33%
Interest-bearing debt is just 27.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.90%
Below 33%
Cash held in interest-bearing accounts and securities is 1.9% of assets, under the one-third limit.
Pass
Receivables
32.22%
Below 49%
Money owed to the company is 32.2% of assets, under the 49% limit.
Pass
Revenue purity
1.52%
Below 5%
Only 1.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 14.7% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Buy. The average target sits +5% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Ultrasound scans rely on these agents yet growth has flatlined
Every hospital that needs a clearer heart scan or cancer image leans on specialised agents like the ones Lantheus supplies. The business clears the ethical screen and posts an 18% profit margin with 23% ROE, yet revenue is advancing only 1% and the shares already sit near analyst targets. That combination leaves almost no margin for error despite the stated fair value sitting 16% higher.
Forward earnings sit on a reasonable 16.9 times multiple and twelve analysts still carry a strong buy label. The difficulty is that low single digit top line growth rarely justifies stretching for modest valuation gaps in a sector where new competitors or reimbursement changes arrive quickly.
The real risk sits in the narrow growth runway and the unknown competitive moat. When revenue barely moves, any slip in margins or loss of key hospital contracts quickly erodes the thin cushion that remains. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LNTH trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-04Markdown · changed$100.87+1.2%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-08-04Markup$99.64-4.7%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-07-18Markup$104.52+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 48% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 26%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (13 analysts) rates it strong buy, with a mean price target of $105.
2026-07-03Markup$104.52+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$104.52Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
